Prognosis

MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Children, Biotechnology, Health, Pharmaceutical, Oncology, Research, Family, Hospitals, Consumer, Science, Clinical Trials, Cancer, Central nervous system, Radiation, Immune system, MAIA, Ohio State University, Cell proliferation, Nationwide Children's Hospital, Nationwide, Hospital, Brain, AACR, Survival rate, Prognosis, CNS, Associate, Survival, Immunotherapy, DIPG

The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.

Key Points: 
  • The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.
  • The study explored the combination of THIO and ionizing radiation (IR) treatments to induce direct anticancer effects and stimulate anti-tumor immunity in diffuse intrinsic pontine glioma (DIPG).
  • DIPG, a very difficult-to-treat and high-risk childhood cancer, is a central nervous system (CNS) tumor that forms in the brainstem.
  • Scientists from Nationwide Children’s Hospital and MAIA have shown that THIO synergistically sensitizes DIPG cells to ionizing radiation (IR), significantly decreasing cell proliferation.

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Recurrence, RFS, Hospital, Metastasis, IB, MSS, Risk, Prognosis, Death, Patient, Survival, Disease, Mortality, Melanoma, Medical imaging

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers 1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM).
  • Stage I CM tumors are considered low risk; however, since stage I encompasses a large group of patients diagnosed, many melanoma-specific deaths are seen in patients initially diagnosed with stage I disease.
  • Thus, there is a clinical gap in the low-risk treatment pathway for stage I patients.
  • The new study in Cancers provides further information that DecisionDx-Melanoma testing could enable more precise risk stratification in stage I melanomas than provided by traditional staging to better inform risk-appropriate clinical management.

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Retrieved on: 
Wednesday, February 21, 2024
Technology, Health, General Health, Public Relations, Investor Relations, Communications, Health Technology, Medical Devices, Genetics, Internet, Mobile, Wireless, Clinical Trials, Hematopoietic stem cell transplantation, Caregiver, Patient, AML, Digital Solutions, ALL, HLA, Chimera, HCT, High, Medicine, Transplant, Prognosis, Cell, HA2, Nucleic acid thermodynamics, MDS, University, Antigen, HA1, Accuracy and precision, Medical device

“Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.

Key Points: 
  • “Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.
  • CareDx will be showcasing its broad portfolio of digital health solutions that address needs in the cellular transplant and therapy ecosystem including workflow management, regulatory reporting, medication management, and remote patient monitoring.
  • Product solution areas include:
    Ottr® Cellular: Designed as a workflow management solution for hematopoietic cellular transplant and cellular therapy centers.
  • Poster 299: Analytical Validation of AlloCell cfDNA - a Highly Sensitive, Precise, and Accurate Cell-Free DNA-Based Test for Allogeneic Cell Therapy Monitoring.

The Inner Circle acknowledges Amir A. Rasheed as a Distinguished Healthcare Professional

Retrieved on: 
Thursday, March 7, 2024
Houston Methodist West Hospital, Inner circle, Iron-deficiency anemia, Multimedia, Houston Methodist Baytown Hospital, Hematology, Blood, North Shore University Hospital, Dow Medical College, SUNY Downstate Medical Center, St Luke's, State university system, Prognosis, Haemophilia, Internal medicine, Leukemia, Patient, Oncology, Medicine, Multiple myeloma, Medical Center, Diagnosis, Anti-transglutaminase antibodies, Lymphoma, Cancer, Hospital

SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

Panoramic Health Launches Scientific Advisory Board to Accelerate Innovation in Kidney Care

Retrieved on: 
Thursday, March 7, 2024
Doctor of Philosophy, Person, Dialysis, Health, University, Acute kidney injury, Health policy, Kidney disease, Diagnosis, Literature, Belding, Michigan, ASN, Bangladesh Technical Education Board, Chronic kidney disease, National Kidney Foundation, NIH, Johns Hopkins, National Academy of Medicine, UNC, Partnership, American Kidney Fund, CKD, Kidney, Biomarker, Prognosis, MPH, Research, Division, Public policy, Population health, FDA, National academy, Entrepreneurship, Society, Patient, Physician, Pharmaceutical industry

TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation. With a focus on uncovering and delivering cutting-edge treatments for patients with kidney disease, the advisory board will play a crucial role in guiding Panoramic Science, the company's clinical research division.

Key Points: 
  • TEMPE, Ariz., March 7, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, is proud to announce the establishment of its Scientific Advisory Board, a distinguished group of clinical leaders and research experts committed to advancing kidney care innovation.
  • "At Panoramic Health, we are dedicated to redefining the standard of kidney care through innovation and collaboration," said Dr. Rajiv Poduval, Co-Founder and Executive Chairman of Panoramic Health.
  • "Our Scientific Advisory Board brings together exceptional expertise that will drive our efforts to enhance patient care and transform the evolving landscape of kidney disease treatment.
  • Panoramic Health leadership team members serving on the advisory board include:
    The establishment of the Scientific Advisory Board underscores Panoramic Health's commitment to driving innovation and improving the lives of patients with kidney disease.

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Wednesday, March 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

BRAINBox Solutions to Present Updated Data at Three Leading Conferences from HeadSMART II and NIH-funded Geriatrics Clinical Trials of BRAINBox TBI Concussion Test

Retrieved on: 
Monday, March 4, 2024
Doctor of Philosophy, Concussion, Emergency, TBI, Poster, Diagnosis, Bangladesh Technical Education Board, School, Alzheimer's disease, Algorithm, Geriatrics, NIH, Emergency medicine, FESC, FACC, Brainbox, Trauma, FACEP, Traumatic brain injury, ATE, Conference, Prognosis, Biomarker, Clinical trial, Serum, Medical school, Blood, Risk, Patient, Baylor College of Medicine, Update, Parkinson's disease, Medical device

RICHMOND, Va., March 4, 2024 /PRNewswire/ -- BRAINBox Solutions today announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded clinical trial in geriatric patients of its BRAINBox TBI™ concussion diagnostic and prognostic test.  Concussion is also known as ATE (Acute Traumatic Encephalopathy) or mTBI (mild traumatic brain injury).

Key Points: 
  • The presentation title is, "Biomarker Profiles Distinguish Geriatric Acute TBI from Dementias:  Results from the HeadSMARTII Geriatric Feasibility Study.
  • "  The poster title is: "Biomarker Profiles Distinguish Geriatric TBI from Dementias:  Results From the HeadSMART Geriatric Feasibility Study."
  • "These presentations highlight the breadth of clinical data being assembled to evaluate the diagnostic and prognostic potential of the BRAINBox TBI test across a spectrum of age groups.
  • "These two trials have made substantial progress, as enrollment in both is expanding and, in the case of HeadSMART II, almost completed," said Donna Edmonds, BRAINBox Solutions' CEO.

Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024

Retrieved on: 
Monday, March 4, 2024
Myenteric plexus, Artificial intelligence, ARIA, Observation, Prognosis, Patient, Donanemab, DSM-IV codes, Fifth, Atrophy, WMH, PET, MRI, Brain, Medical imaging

SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024).

Key Points: 
  • At this conference, Neurophet will introduce Alzheimer's disease treatment related technologies planned to be commercialized such as analysis of the side effect and amyloid-positive prediction.
  • Neurophet AQUA analyzes brain atrophy and white matter hyperintensities (WMH) found in brain MRI of most Alzheimer's disease patients.
  • Neurophet SCALE PET provides quantitative regional amyloid beta deposition, known as the causative agent of Alzheimer's disease, using PET images.
  • Neurophet plans to launch total solution for Alzheimer's disease treatment including ARIA analysis, since Neurophet has the technology to analyze ARIA.

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Retrieved on: 
Friday, March 1, 2024
NSCLC, Progression-free survival, PFS, EGFR, Neoplasm, Magnesium, Diarrhea, FDA, Amivantamab, Food, Cancer, Johnson & Johnson, Nausea, Vomiting, Edema, Risk, ICAN, Constipation, Potassium, IRR, Lung cancer, Toxicity, Neutrophil, Prognosis, COVID-19, NCCN, Fatigue, Death, JNJ, NYU Langone Health, ILD, Drug, Patient, Rash, National Comprehensive Cancer Network, Survival, PAPILLON, Mutation, Appetite, Stomatitis, Pharmaceutical industry

RARITAN, N.J., March 1, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.1 This FDA action converts the May 2021 accelerated approval of RYBREVANT® to a full approval based on the confirmatory Phase 3 PAPILLON study.

Key Points: 
  • The approval of RYBREVANT plus chemotherapy heralds a promising new first-line treatment option for patients newly diagnosed with non-small cell lung cancer where their driver mutation is an EGFR exon 20 insertion," said Marcia Horn**, Executive Director of the Exon 20 Group and CEO of ICAN, International Cancer Advocacy Network.
  • We've seen first-hand the extended survival that Exon 20 Group patients experienced on RYBREVANT plus chemotherapy in the PAPILLON study, and we're delighted that this historic treatment option, which specifically targets the EGFR exon 20 insertion mutation, has been approved."
  • "RYBREVANT plus chemotherapy is the first targeted approach approved for the first-line treatment of patients with NSCLC with EGFR exon 20 insertion mutations.
  • We look forward to building on this latest milestone as we continue to accelerate our transformative lung cancer portfolio."

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

Retrieved on: 
Wednesday, February 21, 2024
Orbis, Classification, PFS, European Commission, EMA, Traffic barrier, Progression-free survival, Confidence interval, Committee, Enzyme, MAA, Research and development, ASCO, Malignancy, Physician, FDA, PDUFA, Society, Glioma, TGR, Microsoft Access, Safety, INDIGO, Prognosis, Civil service commission, HR, CHMP, SNO, IDH, Patient, Medicine, BIRC, Public, Disease, Diagnosis, Mutation, Development, NDA, Priority review, Pharmaceutical industry

BOSTON and SURESNES, France, Feb. 21, 2024 /PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting accelerated assessment for the vorasidenib Marketing Authorization Application (MAA). This innovative targeted therapy is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma. If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth approval across IDH-mutant cancers. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 20, 2024, while the European Commission approval is anticipated in the second half of 2024.

Key Points: 
  • This innovative targeted therapy is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma.
  • If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth approval across IDH-mutant cancers.
  • "In the realm of glioma treatment, innovation has been stagnant for nearly a quarter-century, posing challenges for patients who, post-surgery, may opt to defer treatment due to concerns around potential toxic side effects.
  • "This promising outcome brings hope to patients grappling with IDH-mutant diffuse gliomas, offering a potential breakthrough for those eagerly awaiting a new therapeutic option."